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Abstract
Background: Neural stem/progenitor cells (NPCs) can differentiate into neurons, astrocytes and oligodendrocytes. NPCs are
considered valuable for the cell therapy of injuries in the central nervous system (CNS). However, when NPCs are
transplanted into the adult mammalian spinal cord, they mostly differentiate into glial lineage. The same results have been
observed for endogenous NPCs during spinal cord injury. However, little is known about the mechanism of such fate
decision of NPCs.
Methodology/Principal Findings: In the present study, we have found that myelin protein and Nogo-66 promoted the
differentiation of NPCs into glial lineage. NgR and mTOR-Stat3 pathway were involved in this process. Releasing NgR from
cell membranes or blocking mTOR-STAT3 could rescue the enhanced glial differentiation by Nogo-66.
Conclusions/Significance: These results revealed a novel function of Nogo-66 in the fate decision of NPCs. This discovery
could have profound impact on the understanding of CNS development and could improve the therapy of CNS injuries.
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Introduction
NPCs are a heterogeneous population of mitotically active, self-
renewing and multi-potent cells. They have been isolated from the
adult and embryonic CNS, as well as the fetal CNS in rodent and
human [1,2]. Transplantation of NPCs has being considered as a
potential therapeutic method for CNS injuries. Although NPCs
have the potential for neuronal differentiation in vitro [3,4], the
majority of NPCs would differentiate into astrocytic phenotype
when transplanted into adult non-neurogenic region of CNS such
as the spinal cord[5]. Endogenous NPCs have also been observed
the predominant glial differentiation after the spinal cord injury
[3,6]. Unlike in the peripheral nervous system, the regeneration
ability is extremely limited in adult mammalian CNS because of
myelin-associated inhibitors such as Nogo, MAG, and OMgp[7].
Myelin-associated inhibitors are predominantly expressed by
oligodentrocytes and they are known to inhibit axon regeneration
after injury in adult CNS. Both in vivo and in vitro, the fate
decision of NPCs has been suggested to be controlled not only by
endogenous genes, such as POU genes, Notch genes, and bHLH
genes, but also by exogenous niches. Some outgrowth factors such
as EGF, bFGF, LIF and BMPs as exogenous factors could mediate
the fate decision of NPCs [8,9,10]. Though there is much progress
in NPCs differentiation research, the underlying mechanism of
NPCs fate decision still remains to be elucidated. In the present
study, we have discovered the unknown function of myelin-
associated growth inhibitory proteins which promote the glial
differentiation and inhibit the neuronal differentiation of NPCs.
Results
We have prepared myelin from adult rat spinal cord and
assessed its effect on the differentiation of NPCs (see Fig 1B). After
treated with 1.0 or 5.0 ug/ml myelin, NPCs were inhibited to
differentiate into neuronal cells (b III tubulin positive cells) and
promoted to differentiate into astrocytes (GFAP positive cells) (See
Fig 2B and C). There are many components in myelin. We
wonder if the major myelin components have the similar effects.
Myelin basic protein (MBP) is one of the major myelin proteins,
making up 40% of total myelin protein in CNS. We found that
MBP protein did not regulate the glial and neuronal differentiation
of NPCs (See Fig 2D and E). Some myelin proteins such as Nogo-
A, MAG, and OMgp are axon outgrowth inhibitors in CNS. We
have hypothesized that these axon inhibitory myelin proteins
could mediate the NPCs fate decision. Central to the current
understanding of axon inhibitors is the membrane protein Nogo-
PLoS ONE | www.plosone.org 1 March 2008 | Volume 3 | Issue 3 | e1856Figure 1. Myelin preparation and GST-Nogo-66 expression. (A) Immunofluorescence analysis of Nestin (green) in the primary culture NPCs.
Nuclei were stained by PI (shown in red). Nearly all of the cells were immunostaining positive for Nestin. (B) Western blot analysis detecting Nogo-A
and MBP proteins in myelin preparation with a Nogo-A antibody and a MBP antibody. In myelin preparation from adult rat spinal cord not only MBP,
a major myelin component, was detected, but Nogo-A was also detected. (C) GST-Nogo-66 SDS-PAGE image. Soluble GST-Nogo-66 purified by
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detected by western blot analysis with a Nogo-A antibody (See
Fig 1B).
Nogo-A is predominantly expressed in oligodentrocytes of CNS
and its axon growth inhibiting domain of 66 amino acids (Nogo-
66) is expressed at the extracellular surface[11] and Nogo-66
glutathione-resin was broken and contained about 30% full-length GST-Nogo-66. Full-length GST-Nogo-66 was about 95% in the inclusion bodies.
(D) In vitro analysis of renatured GST-Nogo-66 biological acitivity. Postnatal day 8 rat cerebellar granule neurons were dissociated and placed in
culture on slides coated with poly-L-lysine and later supplemented with GST or GST-Nogo-66. After culturing for 48 hours, cells were fixed,
permeabalized and stained with a b III tubulin antibody (green) and Nuclei were stained by Hoechst 33342 (blue). Micrographs of the treated cultures
showed the inhibitory effects of GST-Nogo-66. (E) Dose-response curve of CGCs treated as in (D) of GST-Nogo-66 protein against neurite length.
Results represent the mean neurite length per cell from two independent experiments, with more than 50 cells being measured in three separate
wells for each treatment. GST-Nogo-66 significantly inhibited neurite outgrowth at 50 nM concentration (2-tailed t test, P,0.01).
doi:10.1371/journal.pone.0001856.g001
Figure 2. The differentiation of NPCs treated by Myelin and MBP, respectively. (A) The immunostaining images of NPCs treated by myelin
and MBP. (B) The result of a b III tubulin antibody immunostaining in NPCs exposure to myelin preparation for 8 days. The proportion of positive cells
was 32.3561.91% and 30.9564.32% in 1.0 ug/ml and 5.0 ug/ml soluble myelin treatment respectively, significantly lower than 45.3865.31% in
5.0 ug/ml BSA control (p,0.05).(C) The result of GFAP antibody immunostaining in NPCs exposure to myelin preparation for 8 days. The proportion
of GFAP positive cells was 28.1961.1.78% and 29.8362.16% in 1.0 ug/ml and 5.0 ug/ml soluble myelin treatment respectively, significantly higher
than 22.5361.85% in 5.0 ug/ml BSA control (p,0.01).(D, E) Purified MBP did not affect the neural differentiation of NPCs.
doi:10.1371/journal.pone.0001856.g002
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soluble, native GST-Nogo-66 protein purified with a glutathione-
resin was broken and only contained about 30% full-length GST-
Nogo-66. Thus we have renatured the GST-Nogo-66 from
inclusion bodies (see Fig 1C). The renatured GST-Nogo-66 had
biological activity and significantly inhibited neurite outgrowth of
rat cerebellar granule neurons (See Fig 1D, E). We thus used the
renatured Nogo-66 to assess its effect on NPCs differentiation in
our study. We observed the differentiation of NPCs treated by
Nogo-66 for 8 days in vitro (See Fig 3). Nogo-66 promoted NPCs to
differentiate into astrogalial cells (GFAP and S-100b positive cells).
We found that 50 nM and 100 nM Nogo-66 could significantly
increase the proportion of GFAP or S-100b immunostaining
positive cells compared to the corresponding dose of GST
treatment. It indicated that Nogo-66 could promote astroglial
differentiation of NPCs, with the similarity of astrocyte differen-
tiation promotion in vivo in previous reports. Meanwhile, both the
NeuN and b III tubulin antibodies were used to identify the
differentiated neurons in immunostaining analysis and Nogo-66
suppressed the neuronal differentiation of NPCs in a dose-
dependent manner. Comparing to b III tubulin expression in
neuron cytoplasm and its axons, NeuN was mostly expressed in
the nuclei. From the two consistent results, we concluded that
Nogo-66 could inhibit the differentiation of NPCs into neurons in
vitro. And the result was further confirmed by western blot analysis
(See Fig 3B). After Nogo-66 treatment, NeuN and b III tubulin
expressions were significantly decreased and GFAP expression was
significantly increased. In addition, no difference of cell apoptosis
percentages between Nogo-66 and GST treatment group was
detected by FACS using Annexin V-FITC and propidine iodide
Figure 3. Astroglial induction of NPCs by Nogo-66 for 8 days. (A) Images of immunocytochemistry. (B) In western blot analysis, both NeuN
and b III tubulin expressions were decreased and GFAP was upregulated in NPCs induced by Nogo-66. (C, D) The quantitative results of anti-NueN,
and b III tubulin antibodies immunocytocheminstry. Nogo-66 significantly inhibited neuronal differentiation in NPCs in dose-dependent manner. (E,
F) The quantitative results of anti-GFAP and S-100bantibodies immunocytocheminstry. Nogo-66 significantly induced NPCs differentiation into
astroglial cells in dose-dependent manner. (G) Apoptosis assay with Annexin V-Fitc and PI staining by FACS. Nogo-66 did not induce significantly
apoptosis compared to GST at day 2, 5, and 8. Data are mean6S.E. Error bars indicate SE. *p,0.05 **p,0.01(n=3). Bar scale=100 um.
doi:10.1371/journal.pone.0001856.g003
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of astroglial differentiation was not the result of the possible
enhanced neuronal cell apoptosis induced by Nogo-66. Due to the
consistent results with the astrocytic marker, GFAP and S-
100bimmunostaining analysis, we considered that Nogo-66 indeed
promoted the glial differentiation of NPCs and GFAP was used as
the marker of glial cells in our experiments.
NgR mediates the inhibitory activity of Nogo-66 on axon
regeneration in CNS [12]. We tested whether NgR was involved
in the glial differentiation of NPCs induced by Nogo-66. To
characterize NgR expression in NPCs, we successfully detected the
NgR mRNA expression by RT-PCR and protein expression by
immunocytochemistry (See Fig 4A and B). NgR is a glycosylpho-
sphatidylinositol (GPI)-linked protein and could be released from
membranes by phosphatidylinositol-specific phospholipase C (PI-
PLC)[12]. As shown in Figure 4C, after releasing NgR with PI-
PLC, the enhanced proportion of GFAP positive cells by Nogo-66
treatment was mostly reversed. To further confirm the above
results, another inhibitor NEP1-40 peptide (AD, USA) was used.
NEP1-40 was a peptide sequences 1–40 aa of the Nogo-66, acts as
the competitive antagonist of NgR and blocks Nogo-66 inhibition
of axonal outgrowth in vitro[11]. Similar to the PI-PLC treatment,
NEP1-40 mostly rescued the astroglial induction by Nogo-66.
Thus we concluded that NgR mediated the astroglial induction of
Nogo-66 in NPCs.
ItiswellknownthatNogo-66inhibits neurite outgrowthand axon
regeneration through the RhoA/RHO kinase (ROCK) pathway
[13,14].Nogo-66activatesRhoA anditsdownstreamtarget ROCK,
and the activity of which can be blocked by the inhibitor Y27632.
Y27632 has been used to reduce the inhibitory effect of Nogo-66 on
axon regeneration. We tested whether the mechanism of astroglial
differentiationpromotionbyNogo-66wasthesameasthatofneurite
growth inhibition. Blocking the ROCK activity in NPCs using
Y27632 did not affect the astroglial differentiation promotion by
Nogo-66(seeFig4D).Thustheastroglialdifferentiationpromotionof
Nogo-66 was not medicated by ROCK pathway.
Janus kinase (JAK)-signal transducers and activators of tran-
scription (STAT3) was involved in the astroglial induction for
NPCs or neural stem cells[15,16,17]. Interestingly, we have found
that Nogo-66 could activate phosphorylation of mammalian target
of rapamycin (mTOR) and phosphorylation of STAT3 at Ser727
and Tyr705 (See Fig 4F). We then used mTOR inhibitor
rapamcyin and JAK/STAT pathway inhibitor AG490 to test
whether mTOR and STAT3 were involved in astroglial induction
by Nogo-66 in NPCs. As shown in Figure 4E, both rapamycin and
AG490 treatment rescued the enhanced astroglial induction by
Nogo-66. In the western blot analysis, we found rapamycin could
abolish the activation of phosphorylation of STAT3 at Ser727 and
Tyr705 (See Fig 4I). AG490 strongly inhibited the phosphoryla-
tion of STAT3 at Tyr705 and weakly inhibit phosphorylation of
STAT3 at Ser727. We also found PI-PLC and NEP1-40 peptide
treatment could rescue the high level phosphorylation of STAT3
at Ser727 and Tyr705 activated by Nogo-66 (See Fig 4G). But
RhoA-ROCK inhibitor Y27632 could not rescue the activated
STAT3 phosphorylation by Nogo-66. In addition, we found
mTOR and STAT3 could form complex in NPCs and rapamycin
treatment decreased the complex formation at the presence of
Nogo-66 by immunoprecipitated with anti-mTOR before western
blot analysis using a STAT3 antibody (See Fig 4 J).
Discussion
Many tissues such as muscle, skin, liver, and peripheral nerve
tissues have remarkable ability to repair and regenerate after
injuries. However, the CNS is very limited to regenerate and this
can cause permanent brain damage or paralyses. Recently some
inhibitory myelin proteins, such as Nogo-A, MAG, and OMgp in
CNS, have been cloned and characterized in neuronal regener-
ation inhibition. But we know little about these myelin associated
regeneration inhibitory proteins in the CNS development and fate
decision of NPCs. Although NPCs have the potential for neuronal
differentiation in vitro [3,4], the majority of endogenous and
exogenous NPCs differentiate into astrocytic phenotype. Because
myelin proteins might be involved in forming the niche for NPCs
in vivo, they could be involved in mediating the fate decision of
NPCs. In this study, we have found that myelin proteins prepared
from adult rat spinal cord mediated NPCs fate decision and
promoted astroglial differentiation. There are many kinds of
components in myelin proteins and MBP was one of the two major
myelin proteins. We did not find that MBP had any effect on the
differentiation of NPCs. Thus, we hypothesized that the myelin
associated inhibitory proteins had the astroglial induction in NPCs
differentiation.
Nogo-A, a potent myelin associated inhibitor, is predominantly
expressed in oligodentrocytes of CNS and its axon growth
inhibiting domain of 66 amino acids (Nogo-66) is expressed at
the extra-cellular surface[11]. In the predicted structure of Nogo-
A, the N and C-terminus are cytosolic and Nogo-66 residue is in
the extracellular or ER lumen localization. But the N terminus of
endogenous Nogo-A has been found exposed on the surface of
some cells such as fibroblasts, DRG neurons, and myoblasts[18].
Nogo-A could be released during CNS injuries and might be
present in the NPCs niche. Thus it may be possible for the
interaction between Nogo-66 and NgR to occur in injured CNS
and mediate the fate decision of NPCs. In our study, Nogo-66, a
potent inhibitory factor in CNS axon regeneration, was found to
have a new role in astroglial induction in NPCs. It provided us a
novel insight into the function of Nogo-A and other myelin
associated factors in the CNS development and regeneration.
Nogo-66 receptor (NgR) mediates the regeneration inhibitory
signal of Nogo-66 [12]. In this study, we have detected that NgR
was expressed in NPCs. After pre-treatment by PI-PLC and
NEP140, the astroglial induction of Nogo-66 was partially
recovered. Furthermore, we have used PI-PLC, NEP1-40 to
recover the activated phosphorylation of STAT3 at Ser727 and
Tyr705 by Nogo-66. Thus the results indicated astroglial induction
signal of Nogo-66 was mediated by NgR.
The mechanism of Nogo-66 in axon regeneration is well known.
After Nogo-66 binding to the NgR, RhoA-ROCK pathway is
activated and axon outgrowth is then inhibited. Y27632 is a
RhoA-ROCK inhibitor and can partially rescue the regeneration
inhibition and promote axon outgrowth of injured neurons both in
vitro and in vivo. After Nogo-66 was found to induce astroglial
differentiation of NPCs, we naturally wondered if the RhoA-
ROCK pathway was also involved in the astroglial induction.
Y27632 treatment did not reverse the astroglial induction of Nogo-
66 and failed to rescue the activated phosphorylation of STAT3
induced by Nogo-66. It suggested that the mechanism of its
astroglial differentiation induction is not dependent on RhoA-
ROCK pathway in NPCs fate decision and different mechanism
should be involved.
Extracellular stimulus and the cellular context activate the
phosphorylation of STAT3. STAT3 requires phosphorylation on
tyrosine (705) and serine (727) residues by independent protein
kinase activities for the maximal activation of target gene
transcription[19]. Members of the JAK/Tyk family of tyrosine
kinases mediate phosphorylation of STAT3 at Tyr705 and mTOR
could mediate phosphorylation of STAT3 at Ser727. Activated
Nogo-66 Regulates NSCs Fate
PLoS ONE | www.plosone.org 5 March 2008 | Volume 3 | Issue 3 | e1856Figure 4. Nogo-66 activated mTOR-STAT3 signaling in NPCs astroglial differentiation. (A) Gel imagine of RT-PCR for NgR mRNA
expression in NPCs. (B) Immunocytochemistry for NgR (green) expression in NPCs. Nuclei were stained by PI (shown in red). (C) PI-PLC and NEP1-40
rescued the astroglial induction by Nogo-66. After PI-PLC or NEP1-40 treatment for 2 hours, the proportion of GFAP positive cells induced by Nogo-
66 was significantly lower than that induced only by Nogo-66 treatment. (p,0.01). (D) The statistical result of GFAP positive cells percentage after
Y27632 (RhoA-ROCK inhibitor) treatment. The astroglial induction of Nogo-66 was not rescued by Y27632. (E) Rapamycin and AG490 rescued the
astroglial induction by Nogo-66. After rapamycin or AG490 treatment for 2 hours, the proportion of GFAP positive cells induced by Nogo-66 was
recovered. (F) Nogo-66 activated the phosphorylation of STAT3 at Ser727 and Tyr705 and phosphorylation of mTOR. After starved for 24 hours in
serum-free DMEM medium, total cell lysates from NPCs treated with GST (G) or Nogo-66 (N) (100 nM) for the indicated time were immunoblotted and
probed with the indicated antibodies. (G) After starved for 24 hours in serum- free DMEM medium, total cell lysates from NPCs not treated (2)o r
treated (+) with PI-PLC (1 U/ml) or NEP1-40 for 2 hours and then stimulated with Nogo-66 (100 nM) for 30 minutes were immunoblotted and probed
with the indicated antibodies. PI-PLC and NEP1-40 could rescue the phosphorylation of STAT3 activated by Nogo-66. (H) Y27632 did not alter the
phosphorylation of STAT3 activated by Nogo0-66. After starved for 24 hours in serum-free DMEM medium, total cell lysates from NPCs not treated
(2) or treated (+) with Y27632 (10 uM) for 2 hours and then stimulated with Nogo-66 (100 nM) for 30 minutes were immunoblotted and probed with
Nogo-66 Regulates NSCs Fate
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tiation in NPCs or neural stem cells [16,20]. Some cytokines, such
as LIF, BMP2 and CNTF promote glial differentiation of NPCs by
activating phosphorylation of STAT3. In the glial differentiation
of neural stem cells induced by BMPs, mTOR associates with
STAT3 and facilitates STAT activation. In this study, Nogo-66
induced astroglial differentiation of NPCs and activated phosphor-
ylation of STAT3 at both Ser727 and Tyr705 and phosphorylation
of mTOR. AG490, a commonly used STAT3 pathway inhibi-
tor[10], could almost entirely rescue the enhanced astroglial
induction of Nogo-66 and this indicated that STAT3 and mTOR
was indeed involved in the glial induction by Nogo-66.
We have found that rapamycin could mostly abolish the
activated phosphorylation of STAT3 at Ser727 and Tyr705. It
indicated that mTOR might also mediate the phosphorylation of
STAT3 at Tyr705, not only at Ser727. The serine-threonine
kinase FKBP12/rapamycin-associated protein (mTOR)/STAT3
pathway played crucial role in glial differentiation induced by
BMPs[16,20] and rapamycin could abolish this effect. Rapamycin
can bind to FKBP12 and inhibit the activation of mTOR [21].
With the similar result, we found that rapamycin completely
abolished the enhanced astroglial differentiation induced by Nogo-
66. In western blot analysis, rapamycin could rescue the activated
phosphorylation of STAT3 induced by Nogo-66. In addition, we
have found that rapamycin treatment could decrease the complex
formation between mTOR and STAT3 by immunoprecipitation
with the mTOR antibody before western blot analysis using a
STAT3 antibody. These results indicated that mTOR regulated
the activation of STAT3 induced by Nogo-66 in NPCs
differentiation. The serine-threonine kinase mTOR is an impor-
tant regulator of cell growth and proliferation by promoting the
synthesis of proteins crucial to cell size and cell cycle progression.
MTOR can catalyze serine phosphorylation of STAT3 and the
activation of STAT3 causes efficient glial differentiation. If
rapamycin binds mTOR, the mTOR-STAT3 will be released
and Nogo-66 will fail to activate the phosphorylation of STAT3.
We thus proposed a model for astroglial induction by Nogo-66 in
NPCs fate decision. The binding of Nogo-66 to NgR activated
mTOR-STAT3 through a still unclear mechanism. MTOR-
STAT3 complex formation is essential for phosphorylation of
STAT3 induced by Nogo-66 in NPCs. The activation of STAT3
then induces the glial differentiation.
Myelin associated factors represent an important environmental
niche for endogenous and transplanted neural stem cells in CNS,
especially at the injured CNS sites. The transplanted neural stem
cells or NPCs in the injured CNS mostly differentiated into
astroglial lineage. In vitro, Nogo-66 has induced NPCs to
differentiate into astroglial cells by activating the mTOR-STAT3
signalling pathway. The glial differentiation promotion by Nogo-
66 may contribute to the low efficient neuronal differentiation in
endogenous and engrafted neural stem cells in CNS. Our study
has provided novel insight into the functions of Nogo-66 and other
myelin associated factors in the CNS development and regener-
ation. Further studies could help to identify important cellular
molecules for evolving pharmacological, gene and stem cell
therapeutic interventions in CNS regeneration.
Materials and Methods
Antibodies and Reagents
Nogo-R (Catalog #: sc-25659, Santa Cruz Biotechnology);
GFAP (Catalog #: ab929, ABCAM); NeuN and b III tubulin
(Upstate); S-100 beta and a-tubulin (Sigma); P-STAT3 (Ser727),
P-STAT3 (Tyr 705) and STAT3 (CST), P-mTOR and mTOR
(CST);Nestin (ABCAM) ; Nogo-A (#Nogo-A 12-A, AD);MBP
(Boster, China).Myelin basic protein (MBP), bovine puried
(Upstate). Rapamycin (Sigma); AG490 (Biosource); Y27632
(Sigma); PI-PLC (Sigma); NEP1-40 (Calbiochem).
Cell Culture and Treatments
NPCs were prepared as described previously [22] with slightly
modification. The telencephalon of neonatal Sprague Dawley (SD)
rats were carefully dissected in serum-free DMEM/F12 medium
and triturated. The cell suspension was cultured in 25 cm
2 tissue
culture flask (Corning) in serum-free DMEM/F12 medium with
B27 supplement, 10 ng/ml bFGF(PeproTech EC), and 20 ng/ml
EGF(PeproTech EC). After 8-day culture, neurosphere were
formed and the cells were enzymatically dissociated for following
experiments.
For Immunocytochemistry, NPCs were plated in 48 well culture
plate (Corning) at 10
4 cells per well. The maintaining medium was
serum-free DMEM (high glucose) with N2 supplement. In the
presence of myelin, MBP, GST, or Nogo-66 for 8-day, the
terminal differentiated cells was assessed by immunocytochemis-
try. For the biochemical assays, cells were treated with factors and
harvested at the time points mentioned in the figure legends.
Myelin Preparation
Myelin preparation from adult rat spinal cord was produced
according to previous report[23]. To isolate myelin, tissue is
homogenized in 0.3 M sucrose and layered on a gradient of 1.23
and 0.85 M sucrose. Samples are centrifuged for 45 min at 75
000 g and the crude myelin fraction is collected at the 0.85/
1.23 M interface. Crude myelin is washed twice by osmotic shock,
resuspended in 0.32 M sucrose, layered over 0.85 M sucrose,
centrifuged, and collected from the 0.32/0.85 M interfaces. After
removal of excess sucrose myelin is resuspended 1:1 in DMEM,
homogenized and stored at 280uC until use.
Apoptosis Assay
Cell apoptosis was measured with FACS. For each sample,
approximately 1610
6 cells were washed twice with PBS and then
resuspended in 200 mL of binding buffer (10 mM HEPES, 140 mM
NaCl, 5 mM CaCl2). 10 mL of Annexin V-FITC stock solution
(20 mg/mL) was added to the cells and incubated for 30 min at 4uC.
The cells were then further incubated with 5 mLp r o p i d i n ei o d i d e
(PI, 50 mg/mL) and were immediately analyzed on a FACSC-LSR
(Becton-Dickton) equipped with Celluest (Becton-Dickton) software.
GST-Nogo-66 Protein Expression
Nogo-66, a portion of Nogo-A mRNA encoding the 66-residue
lumenal/extracellular fragent was ampilified and ligated to
pGEX-4T-1 plasmid (Amersham Biosciences) to yield a prokary-
the indicated antibodies. (I) Rapamycin could inhibit the activated phosphorylation of STAT3 induced by Nogo-66. AG490 strongly inhibited
phosphorylation of STAT3 at Tyr705. After starved for 24 hours in serum-free DMEM medium, total cell lysates from NPCs not treated (2) or treated
(+) with rapamycin (50 uM) or AG 490 (3ug/ml) for 2 hours and then stimulated with Nogo-66 (100 nM) for 30 minutes were immunoblotted and
probed with the indicated antibodies. (J) Rapamycin treatment decreased the complex formation between mTOR and Stat3 in NPCs at the presence
of Nogo-66. Nondenatured whole cell lysates were immunoprecipitated with an mTOR antibody before western blot analysis using anti-STAT3 and
mTOR, respectively. Data are mean6S.E. Error bars indicate SE. *p,0.05 **p,0.01 (n=3).
doi:10.1371/journal.pone.0001856.g004
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transformed with the plasmid was induced with 0.1 mM IPTG.
Soluble, native GST-Nogo-66 protein purified using a glutathione-
resin was broken and only contained about 30% full-length GST-
Nogo-66. Most of the GST-Nogo-66 proteins were in inclusion
bodies and were full-length (see Fig 1). GST-Nogo-66 from
inclusion bodies was renatured by dilution renature method.
Briefly, the recombinant protein was isolated from Escherichia coli
as inclusion bodies by sonication and centrifugation, and then
dissolved with 8 M urea and renatured by dilution using renature
buffer (0.5 M NaCl, 5 mM GSH, 1 mM GSSH, 50 mM, 50 mM,
1 mM EDTA-Na2). The biological activity of the GST-Nogo-66
was tested according to previous report[24]. Postnatal 8 days rat
cerebellar granule neurons (CGCs) were dissociated and placed in
culture on slides coated with poly-L-lysine with DMEM/F12
containing 10% FBS for 30 min and then supplemented with
control GST protein, or the inhibitory proteins GST-Nogo-66 in
DMEM/F2 medium plus N2 supplement . After growth for
48 hours, cells were fixed, permeabilized and stained with a beta-3
tubulin antibody. Micrographs of the treated cultures show the
inhibitory effects of GST-Nogo-66. In this study, the renatured
GST-Nogo-66 with biological activity was used.
Immunoblotting and Immuoprecipitation
Cell lysates were subjected to 8% SDS–PAGE and transferred to
nitrocellulose membranes.For immunoprecipitation, 500 ul(500 ug)
cell lysates were incubated with anti-mTOR antibody (1:100)
overnight at 4uC. After incubation with protein A–Sepharose (1:1
vol/vol), the immune complexes were washed twice with PBS and
heated to 70C in SDS-PAGE loading buffer. The blots were probed
with indicated primary antibodies, followed by secondary antibodies
conjugated with HRP. Fluorescent signals were detected with ECL
system (Pierce). For immunoblotting, primary antibodies were
diluted as follow: NeuN, b III tubulin, a-tubulin, P-STAT3
(Ser727), P-STAT3 (Tyr 705), STAT3 (CST), P-mTOR and mTOR
(CST) at 1:1000; Nogo-A at 1:300, MBP at 1:200, GFAP 1:100.
Immunocytochemistry
NPCs were plated in 48 well culture plate (Corning) at 10
4 cells
per well. After 8-day GST or GST-Nogo-66 administration, cells
were fixed by 4% formaldehydum polymerisatum (Merck) for
immunocytochemistry. Immunocytochemistry was performed
using theb III tubulin, neuronal nuclei (NeuN), and GFAP
antibody, respectively. The primary antibodies were incubated
overnight at 4uC and then incubated with the secondary FITC-
conjugated antibodies and Hoechst33342 (1 mg/ml) for 1 hr at
room temperature. Primary antibodies were diluted as follow:
NeuN and b III tubulin at 1:800; NgR at 1:400, GFAP at 1:6; and
Nestin at 1:600. No immune IgG was used as control and did not
find nonspecific staining. After immunostaining of differentiated
cells, images of Hoechsst dye staining neucleus DNA (to identify
the total number of cells in the field) and the respective antigens
were captured with a Zeiss Axiovert 200 (Carl Zeiss). The
respective images were overlaid and the percentage of antigen
positive cells was calculated. Six random fields/well from three
replicated wells were counted.
RT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen life
technologies) according to the manufacturer’s protocol. Primers
were designed as following: NgR sense 59 GGGCAACCT-
CACGCGCATCT 39, NgR anti-sense 59 CGGGCAAAGTCC-
CAAAT 39; b-actin sense 59 GTCCCTGTATGCCTCTGGTC
39, b-actin anti-sense 59 GGTCTTTACGGATGTCAACG 39.
Primers for b-actin gene were cycled 24 times and those for others
were cycled 28 times.
Statistical analysis
Data were mean6S.E. Statistical analyses in this study were
performed with ANOVA. When significant differences were
found, post-hoc comparisons were made using the Tukey honestly
significant difference test. *P,0.05 was considered significant in all
instances.
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